Comparative Pharmacology
Head-to-head clinical analysis: ASBRON versus BRONKODYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASBRON versus BRONKODYL.
ASBRON vs BRONKODYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Asbron is a combination product containing theophylline and guaifenesin. Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular cAMP levels, resulting in bronchodilation and anti-inflammatory effects. Guaifenesin is an expectorant that increases respiratory tract fluid secretions to reduce mucus viscosity.
Bronkodyl contains theophylline, a xanthine derivative. It acts as a bronchodilator by inhibiting phosphodiesterase, increasing cyclic AMP levels, leading to relaxation of bronchial smooth muscle. Additionally, it blocks adenosine receptors and may have anti-inflammatory effects.
1-2 tablets (130-260 mg theophylline equivalent) orally every 6-8 hours; maximum 6 tablets/day.
Theophylline extended-release: 300-600 mg orally every 12 hours; target serum concentration 5-15 mcg/mL.
None Documented
None Documented
4-6 hours in adults; prolonged to 8-12 hours in hepatic impairment or elderly patients
Terminal elimination half-life is 3–8 hours in non-smoking adults, 1–5 hours in smokers, and 20–30 hours in premature neonates; clinical context: half-life increases in hepatic impairment, heart failure, and with certain medications (e.g., cimetidine, fluoroquinolones).
Primarily renal (70-80% as unchanged drug), biliary/fecal (~15-20% as metabolites and unchanged drug)
Renal: approximately 90% as theophylline and its metabolites (1,3-dimethyluric acid, 3-methylxanthine, 1-methyluric acid); biliary/fecal: <10%.
Category C
Category C
Bronchodilator
Bronchodilator